Paper Details

  1. Home
  2. Paper Details

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

Author: AdachiJ D, DaizadehN S, FerrariS, KendlerD L, LewieckiE M, LibanatiC, LippunerK, MillerP D, O'MalleyC D, ReginsterJ-Y, TörringO, WagmanR B, WangA, ZapalowskiC

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Long-term denosumab treatment (7 years) for osteoporosis was associated with a significant decrease in nonvertebral fractures compared to the first 3 years of treatment. This suggests a continued benefit with long-term therapy.
Paper Details　
Original Abstract of the Article :
Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in years 4-7 versus years 1-3. This is the first demonstration of a further benefit on fracture outcom...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656715/

データ提供：米国国立医学図書館（NLM）

Long-Term Denosumab Treatment for Osteoporosis

The study delves into the world of osteoporosis, a condition that weakens bones, making them more prone to fractures. It's like studying the effects of a long drought on a desert landscape, leading to erosion and fragility. The research focuses on denosumab, a medication used for long-term treatment of osteoporosis, and its effects on nonvertebral fracture rates. It's like exploring a new irrigation system designed to strengthen and protect the desert landscape from further erosion.

The study found that denosumab significantly reduced nonvertebral fracture rates in postmenopausal women with osteoporosis over a 7-year period. This suggests that long-term treatment with denosumab can provide sustained protection against fractures. It's like a long-lasting irrigation system, continuously supplying water and strengthening the desert landscape over time.

The study also investigates the impact of denosumab on hip bone mineral density, a crucial measure of bone health. It's like evaluating the health of the desert landscape by measuring the density of its sand dunes.

Denosumab: A Boon for Bone Health

The research reveals that denosumab can significantly reduce the risk of nonvertebral fractures in patients with osteoporosis over an extended period. It's like a long-lasting irrigation system that continuously replenishes the desert landscape, preventing further erosion and strengthening its resilience. This study offers hope for individuals struggling with osteoporosis, providing a potential solution for maintaining bone health and preventing fractures.

Strengthening Bones in the Desert of Osteoporosis

The research suggests that long-term denosumab treatment can significantly reduce the risk of fractures in patients with osteoporosis. It's like finding a sustainable irrigation system that can help maintain the health and resilience of the desert landscape. However, it's important to consult with a healthcare professional to determine the best treatment approach for your specific condition.

Dr.Camel's Conclusion

Denosumab shows promise as a long-term treatment for osteoporosis. It's like a reliable irrigation system that can help sustain the health and resilience of the desert landscape. However, as always, consult with your healthcare provider to determine the best course of action for your individual needs.

Date :
  1. Date Completed 2016-09-15
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

26068295

DOI: Digital Object Identifier

PMC4656715

Related Literature

Article Analysis
・Effective treatment of osteoporosis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.